Mochida Pharmaceutical Company, Ltd.
Quick facts
Phase 3 pipeline
- Icosapent (MND-2119) · Cardiovascular
Icosapent is a purified form of the omega-3 fatty acid eicosapentaenoic acid (EPA) that reduces triglycerides and modulates lipid metabolism.
Phase 1 pipeline
Competitive intelligence
For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors: